journal
https://read.qxmd.com/read/38647036/therapeutic-plasma-exchange-as-an-intervention-for-gemtuzumab-ozogamicin-impaired-hemoglobin-scavenging-a-case-and-systematic-review
#1
Brian D Adkins, Daniel K Noland, Tamra Slone, Arhanti Sadanand
Gemtuzumab ozogamicin (GO) is a CD33 monoclonal antibody-drug conjugate currently in use to treat myeloid malignancies. A unique adverse effect of this medication is destruction of CD33 positive macrophages resulting in reduced clearance of free hemoglobin leading to grossly red plasma. This build-up of free hemoglobin can potentially lead to end organ damage and prevent performance of clinically necessary laboratory evaluation. We present a case of a pediatric patient who developed this adverse effect and was successfully treated with therapeutic plasma exchange (TPE)...
June 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38634471/collection-efficiency-of-double-versus-single-needle-extracorporeal-photopheresis
#2
JOURNAL ARTICLE
Yandy Marx Castillo-Aleman, Shinnette Lumame, Charisma Castelo, Yendry Ventura-Carmenate, Fatema Mohammed Al-Kaabi
No abstract text is available yet for this article.
June 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38634442/suspected-autoimmune-encephalitis-a-retrospective-study-of-patients-referred-for-therapeutic-plasma-exchange
#3
JOURNAL ARTICLE
Elizabeth P Crowe, Luisa A Diaz-Arias, Ralph Habis, Sonja O Vozniak, Romergryko G Geocadin, Arun Venkatesan, Aaron A R Tobian, John C Probasco, Evan M Bloch
INTRODUCTION: Autoimmune encephalitis (AE) comprises a heterogeneous group of autoantibody-mediated disorders targeting the brain parenchyma. Therapeutic plasma exchange (TPE), one of several first-line therapies for AE, is often initiated when AE is suspected, albeit prior to an established diagnosis. We sought to characterize the role of TPE in the treatment of suspected AE. METHODS: A single-center, retrospective analysis was performed of adults (≥18 years) who underwent at least one TPE procedure for "suspected AE...
June 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38634439/beyond-traditional-venous-access-midline-catheter-use-in-pediatric-apheresis
#4
JOURNAL ARTICLE
Kira Geile, Kevin Barton, Raja Dandamudi
The objective of this study was to assess the use of midline catheters as venous access for apheresis procedures in pediatric patients. A retrospective analysis of medical records was conducted from September 2019 to June 2022 to evaluate the safety and efficacy of midline catheters for therapeutic pediatric apheresis. During the study period, a total of 121 procedures were inserted in 22 unique patients. The age of the subjects ranged from 2.7 to 21 years. The blood flow rates achieved with midline catheters met or exceeded the recommended rates for apheresis in children (40 mL/min), by the Wilcoxon signed-rank test (p < 0...
June 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38634432/assessing-the-clinical-efficacy-of-low-volume-therapeutic-plasma-exchange-in-achieving-recovery-from-acute-liver-failure-induced-by-yellow-phosphorous-poisoning
#5
JOURNAL ARTICLE
Ancy Ninan, Ganesh Mohan, Vishal Shanbhag, Deepika Chenna, Shamee Shastry, Shwethapriya Rao
BACKGROUND: Acute liver failure (ALF) following yellow phosphorous (YP) ingestion is similar to acetaminophen-induced ALF and it has become a public concern in our region. This study assessed low volume therapeutic plasma exchange (LV-TPE) efficacy in improving the transplant free survival in YP poisoning. METHODS: Adult patients with toxicology reports of YP and ALF requiring critical care were included in the study. LV-TPE was planned for three consecutive days and three more if required...
June 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38634419/apheresis-practice-variation-during-the-covid-19-pandemic-results-of-a-survey
#6
JOURNAL ARTICLE
Yvette C Tanhehco, Mohamed Alsammak, Vishesh Chhibber, Nnaemeka Ibeh, Yanhua Li, Laura D Stephens, Daniel K Noland, Ding Wen Wu, Nicole D Zantek, Phillip J DeChristopher, Marisa Claudia Saint Martin, Wen Lu, Gay Wehrli
BACKGROUND: The COVID-19 pandemic affected healthcare delivery across all specialties including apheresis. To describe the changes in apheresis service practices that occurred during the pandemic, the American Society for Apheresis (ASFA) Apheresis Medicine Attending Physician Subcommittee conducted a survey study. STUDY DESIGN AND METHODS: A 32-question survey was designed and distributed to 400 ASFA physician members on September 7, 2022. Attending physicians responded to questions about whether and how apheresis service practices changed during the COVID-19 pandemic compared with the time period prior to the pandemic in terms of: (1) procedure types and volumes, (2) patient consultation workflow, and (3) the use of telemedicine...
June 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38613464/special-issue-abstracts-from-the-american-society-for-apheresis-45th-annual-meeting-april-17-19-2024
#7
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38404046/improved-survival-in-covid-19-related-sepsis-and-ards-treated-with-a-unique-triple-therapy-including-therapeutic-plasma-exchange-a-single-center-retrospective-analysis
#8
JOURNAL ARTICLE
Philip Keith, Rebecca Inez Caldino Bohn, Trung Nguyen, L Keith Scott, Monty Richmond, Matthew Day, Carol Choe, Linda Perkins, Rebecca Burnside, Richard Pyke, Ben Rikard, Amanda Guffey, Arun Saini, H J Park, Joseph Carcillo
BACKGROUND: Throughout the COVID-19 pandemic, the mortality of critically ill patients remained high. Our group developed a treatment regimen targeting sepsis and ARDS which we labeled "triple therapy" consisting of (1) corticosteroids, (2) therapeutic plasma exchange (TPE), and (3) timely intubation with lung protective ventilation. Our propensity analysis assesses the impact of triple therapy on survival in COVID-19 patients with sepsis and ARDS. METHODS: Retrospective propensity analysis comparing triple therapy to no triple therapy in adult critically ill COVID-19 patients admitted to the Intensive Care Unit at Lexington Medical Center from 1 March 2020 through 31 October 2021...
February 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38390668/writing-manuscripts-for-peer-review
#9
REVIEW
Robert Weinstein
Little instruction in writing manuscripts for peer review is provided in nursing school or medical school. To relatively inexperienced would-be authors, including junior physicians and allied health professionals, this avenue of professional communication may sometimes seem to be unattainable. Yet many of them are energetic and insightful, and have the potential to make contributions to the literature. This article aims to provide an explanation of the components of the peer review manuscript and advice regarding how to go about writing one so as to overcome the writer's block that inexperienced authors may frequently experience...
February 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38353113/real-world-evidence-of-heparin-and-citrate-use-in-extracorporeal-photopheresis-a-hypothesis-generating-data-review-of-device-settings-and-performance
#10
JOURNAL ARTICLE
Laura S Connelly-Smith, James Griffin, Albert T Leung, Francesca Gennari
Extracorporeal photopheresis (ECP) is widely used for the treatment of cutaneous T-cell lymphoma, graft-vs-host disease, and other immune-related conditions. To avoid clotting during treatment, the ECP system used must be effectively primed with an anticoagulant. Heparin is the recommended anticoagulant for the THERAKOS CELLEX System, but acid citrate dextrose-A (ACDA) is often used. We compared system performance between these two anticoagulants for this ECP system. Deidentified data for ECP device performance were obtained at each treatment session, from automatically logged Smart Cards or labels completed by device operators...
February 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38334173/use-of-therapeutic-plasma-exchange-to-remove-lipoprotein-x-in-a-patient-with-vanishing-bile-duct-syndrome-presenting-with-cholestasis-pseudohyponatremia-and-hypercholesterolemia-a-case-report-and-review-of-literature
#11
JOURNAL ARTICLE
Yujung Jung, Heather A Nelson, David Ming-Hung Lin
INTRODUCTION: Lipoprotein X (Lp-X) is an abnormal lipoprotein found in multiple disease conditions, including liver dysfunction and cholestasis. High Lp-X concentrations can interfere with some laboratory testing that may result in spurious results. The detection of Lp-X can be challenging, and there is currently a lack of consensus regarding the management of Lp-X other than treating the underlying disease. CASE PRESENTATION: A 42-year-old female with Hodgkin's lymphoma treated with dexamethasone, high dose cytarabine and cisplatin and vanishing bile duct syndrome confirmed by liver biopsy presented with cholestasis, pseudohyponatremia (sodium, 113 mmol/L; reference range 136-146 mmL/L; serum osmolality, 303 mOsm/kg), and hypercholesterolemia (> 2800 mg/dL, reference range < 200 mg/dL)...
February 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38334167/evaluation-of-a-scoring-system-for-vein-suitability-in-platelet-apheresis-donors
#12
JOURNAL ARTICLE
Shahida Noushad, Abhishekh Basavarajegowda, Esha Toora, Dibyajyoti Sahoo, K M Hari Priya
INTRODUCTION: Donor vein assessment for the selection of good quality veins is crucial for a successful apheresis procedure. This study intends to find out the effectiveness of a vein assessment scoring tool (VST) used and found to be effective in selecting whole blood donors to reduce the difficulty in identifying good quality veins for the plateletpheresis procedure. MATERIALS AND METHODS: This was a prospective observational study on platelet apheresis donors with the application of a VST consisting of three vein descriptor parameters (vein visibility, vein palpability, and vein size) with 5 Likert-type responses constituting a score of 0-12 for each arm...
February 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/37990778/a-retrospective-study-to-investigate-the-efficacy-and-safety-of-granulocyte-and-monocyte-adsorptive-apheresis-in-patients-with-primary-sclerosing-cholangitis-with-ulcerative-colitis
#13
JOURNAL ARTICLE
Ayumi Ito, Shun Murasugi, Maria Yonezawa, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
BACKGROUND AND AIMS: Primary sclerosing cholangitis has a poor prognosis and can be accompanied by ulcerative colitis. Infection control is essential, so immunosuppressive drugs should ideally be preferably. Granulocyte and monocyte adsorptive apheresis does not suppress the immune system and is used to treat ulcerative colitis. Therefore, this study investigated the efficacy and safety of granulocyte and monocyte adsorptive apheresis in patients with primary sclerosing cholangitis and ulcerative colitis...
February 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38186371/safety-and-efficacy-of-peripheral-blood-stem-cells-collection-in-healthy-children-and-pediatric-patients-with-thalassemia-major-weighing-20%C3%A2-kg-or-less
#14
JOURNAL ARTICLE
Libai Chen, Jianyun Wen, Xiaoxiao Xu, Jing Du, Yongsheng Ruan, Xiaoqin Feng, Juan Li, Yuelin He, Xuedong Wu
BACKGROUND: Peripheral blood stem cell (PBSC) collection in children poses challenges due to their small size, low body weight (BW), and unique pediatric physiology, especially among children weighing 20 kg (kg) or less. METHODS: PBSC collection data of both healthy children and patients with thalassemia major (TM) weighing 20 kg or less between January 2013 and December 2020 were reviewed. Moreover, PBSCs characteristics along with various aspects of efficiency and safety between healthy donors and patients with TM were compared...
January 8, 2024: Journal of Clinical Apheresis
https://read.qxmd.com/read/38098278/a-single-center-retrospective-study-comparison-between-centrifugal-separation-plasma-exchange-with-acd-a-and-membrane-separation-plasma-exchange-with-heparin-on-acute-liver-failure-and-acute-on-chronic-liver-failure
#15
JOURNAL ARTICLE
Xin-Fang Zhu, Jia-Qiang Li, Tian-Tian Liu, Yuan Wang, Yao Zhong, Qing-Mei Gao, Qi Zhang, Kang-Kang Yu, Chong Huang, Ning Li, Qing Lu, Wen-Hong Zhang, Ji-Ming Zhang, Rong Xia, Jian-Ming Zheng
The purpose of this retrospective study is to compare the efficacy and safety of the centrifugal separation therapeutic plasma exchange (TPE) using citrate anticoagulant (cTPEc) with membrane separation TPE using heparin anticoagulant (mTPEh) in liver failure patients. The patients treated by cTPEc were defined as cTPEc group and those treated by mTPEh were defined as mTPEh group, respectively. Clinical characteristics were compared between the two groups. Survival analyses of two groups and subgroups classified by the model for end-stage liver disease (MELD) score were performed by Kaplan-Meier method and were compared by the log-rank test...
December 14, 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/38054256/microrna-and-granulocyte-monocyte-adsorption-apheresis-combotherapy-after-inadequate-response-to-anti-tnf-agents-in-ulcerative-colitis
#16
JOURNAL ARTICLE
Esteban Sáez-González, Inés Moret-Tatay, Guillermo Bastida, Mariam Aguas, Marisa Iborra, Pilar Nos, Belén Beltrán
BACKGROUND: Ulcerative colitis (UC) is an inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract, affecting millions of individuals throughout the world, and producing an impaired health-related quality of life. Granulocyte and monocyte apheresis (GMA) is a therapeutic option for UC management to induce remission by selective removal of activated leukocytes from bloodstream. Despite the knowledge of the important role of epigenetics in UC pathogenesis, and in the response to different treatments, nothing is known about the role of microRNAs in GMA therapy in UC patients...
December 6, 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/38037757/validation-of-nivestym-compared-to-neupogen-an-nmdp-analysis
#17
JOURNAL ARTICLE
Joseph Maakaron, Katie Picotte, Kevin Tram, Ruth Bakken, Jason Oakes, Meghann Cody, John Miller, Steven M Devine, Heather E Stefanski
No abstract text is available yet for this article.
December 1, 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/37519096/therapeutic-leukocytapheresis-for-leukostasis-in-chronic-lymphocytic-leukemia-a-case-report-and-literature-review
#18
REVIEW
Thomas Auen, Pranav Renavikar, Esther Habib, Scott A Koepsell
Chronic lymphocytic leukemia (CLL) is a clonal mature B-cell neoplasm with a typically indolent clinical course. Though most clinicians follow these neoplasms through observation alone, an aggressive transformation to prolymphocytic leukemia, diffuse large-B-cell lymphoma (Richter transformation) or classical Hodgkin lymphoma requires immediate attention. We present a case of extreme leukocytosis (>1 million/μL) in a previously diagnosed CLL patient. Due to symptomatic leukostasis, she was started on cytoreductive therapies including leukocytapheresis...
December 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/37519071/botulism-mimicking-guillain-barre-syndrome-the-question-of-plasma-exchange-in-an-unusual-case-of-acute-paralysis
#19
Juan J Silva Campos, Elizabeth Abels, Henry M Rinder, Christopher A Tormey, Jeremy W Jacobs
Guillain-Barré syndrome (GBS) is an immune-mediated polyradiculoneuropathy and the most common cause of acute flaccid paralysis worldwide. GBS classically presents with acute, progressive, ascending weakness, reduced to absent reflexes, and albuminocytological dissociation on cerebrospinal fluid (CSF) analysis. Botulism is a neurotoxin-mediated acute descending flaccid paralysis with cranial nerve palsies and dysautonomia. Botulism in adults is caused by ingestion/inhalation of botulinum toxin or wound infection with Clostridium botulinum...
December 2023: Journal of Clinical Apheresis
https://read.qxmd.com/read/37990775/therapeutic-plasma-exchange-in-refractory-susac-s-syndrome-a-brief-report
#20
JOURNAL ARTICLE
Ryan D Salazar, Krystol R Weidner, Caroline R Alquist
Susac's syndrome (SuS) is an autoimmune endotheliopathy that typically presents with the clinical triad of encephalopathy, hearing loss, and branch retinal artery occlusion. It has a wide range of possible presentations, and its pathogenesis remains uncertain. Fulminant and refractory cases are difficult to treat, and no standard treatment protocol has been established. However, therapeutic plasma exchange (TPE) has been described as an adjunctive therapy in several SuS cases. Herein we present a case of a 63-year-old male with debilitating encephalopathy and recent hearing and vision loss, who responded favorably to TPE...
November 21, 2023: Journal of Clinical Apheresis
journal
journal
28458
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.